alendronate has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 6 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bisphosphonate use, in particular pamidronate, improved pain scores, analgesic requirement and musculoskeletal function in patients with osteonecrosis occurring as a complication of childhood ALL therapy." | 5.14 | Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL). ( Carter, T; Cole, C; Kotecha, RS; Lee, SJ; Murray, KJ; Powers, N, 2010) |
| "Osteopenia is a common consequence of the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents, due predominantly to glucocorticosteroid therapy." | 2.73 | Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience. ( Barr, RD; Lethaby, C; Naronha, M; Sala, A; Webber, C; Wiernikowski, J, 2007) |
| "Alendronate therapy was tolerated well." | 2.71 | Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study. ( Atkinson, SA; Barr, RD; Guo, CY; Webber, C; Wiernikowski, JT; Wright, M, 2005) |
| "Low bone mineral density is encountered in children with acute lymphoblastic leukemia (ALL) before, during, and after treatment." | 1.91 | Safety and Efficacy of Alendronate to Treat Osteopenia in Children During Therapy for Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of Sequential Outcomes. ( Athale, U; Barr, RD; Cranston, A; Farncombe, T; MacDonald, P; Virdee, M, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| MacDonald, P | 1 |
| Cranston, A | 1 |
| Virdee, M | 1 |
| Farncombe, T | 1 |
| Athale, U | 1 |
| Barr, RD | 3 |
| Amin, NL | 1 |
| James, RM | 1 |
| Phillips, R | 1 |
| Kotecha, RS | 1 |
| Powers, N | 1 |
| Lee, SJ | 1 |
| Murray, KJ | 1 |
| Carter, T | 1 |
| Cole, C | 1 |
| Wiernikowski, JT | 1 |
| Webber, C | 2 |
| Guo, CY | 1 |
| Wright, M | 1 |
| Atkinson, SA | 1 |
| Tragiannidis, A | 1 |
| Athanassiadou, F | 1 |
| Papageorgiou, T | 1 |
| Petsatodis, G | 1 |
| Lethaby, C | 1 |
| Wiernikowski, J | 1 |
| Sala, A | 1 |
| Naronha, M | 1 |
1 review available for alendronate and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
QUESTION 1: Should we be using bisphosphonates for osteonecrosis complicating childhood acute lymphoblastic leukaemia?
Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Fe | 2016 |
3 trials available for alendronate and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL).
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Alendronate; Antineoplastic Combined Chem | 2010 |
Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.
Topics: Absorptiometry, Photon; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Alendronate; Bone | 2005 |
Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience.
Topics: Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; C | 2007 |
2 other studies available for alendronate and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Safety and Efficacy of Alendronate to Treat Osteopenia in Children During Therapy for Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of Sequential Outcomes.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, | 2023 |
Severe skeletal complications in a child with acute lymphoblastic leukemia.
Topics: Alendronate; Bone Density; Child; Female; Femur Neck; Humans; Lumbar Vertebrae; Osteoporosis; Precur | 2006 |